Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Continuous therapy improves multiple myeloma outcomes

Continuous therapy improves multiple myeloma outcomes

Patients with newly diagnosed multiple myeloma receive significant progression-free and overall survival benefits from continuous treatment compared with fixed-duration therapy, suggests a pooled analysis. [More]
Discovery could help in development of novel cancer-selective viral therapies

Discovery could help in development of novel cancer-selective viral therapies

Every organism--from a seedling to a president--must protect its DNA at all costs, but precisely how a cell distinguishes between damage to its own DNA and the foreign DNA of an invading virus has remained a mystery. [More]
New test predicts breast cancer relapse months in advance

New test predicts breast cancer relapse months in advance

UK-based researchers have developed a blood test that can predict whether patients with breast cancer will experience a relapse after receiving treatment, months before tumors are visible using hospital scans. [More]
Nitroglycerin can be repurposed to treat cancer, researchers find

Nitroglycerin can be repurposed to treat cancer, researchers find

For over a century, nitroglycerin has been used medically - particularly in the treatment of angina, or chest pain. It is a safe, cheap and effective treatment. Now, according to the latest study in ecancermedicalscience, researchers find that nitroglycerin is the latest in a series of medicines that could be repurposed to treat cancer. [More]
Physical inactivity poses important clinical, public health and fiscal challenges for the U.S.

Physical inactivity poses important clinical, public health and fiscal challenges for the U.S.

What do a prominent physiologist and two-time survivor of pancreatic cancer and a world-renowned researcher whose landmark discoveries on aspirin, drug therapies of proven benefit and therapeutic lifestyle changes that have saved more than 1.1 million lives have in common? They are both passionate about the importance of regular physical activity in reducing risks of dying from heart attacks and strokes, as well as developing diabetes, hypertension and colon cancer. And more importantly, enhancing mental health and fostering healthy muscles, bones and joints in all Americans from childhood to the elderly. [More]
Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Alternative medicines are widely thought to be at least harmless and very often helpful for a wide range of discomforts and illnesses. However, although they're marketed as "natural," they often contain active ingredients that can react chemically and biologically with other therapies. [More]
ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the seven funding grants, including ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Award and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award, will support studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. [More]
Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. [More]
Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

In preliminary research, the detection of persistent leukemia-associated genetic mutations in at least 5 percent of bone marrow cells in day 30 remission samples among adult patients with acute myeloid leukemia was associated with an increased risk of relapse and reduced overall survival, according to a study in the August 25 issue of JAMA. [More]
Study reveals how inflammation triggers colon cancer cells to metastasize

Study reveals how inflammation triggers colon cancer cells to metastasize

A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois, M.D., Ph.D., has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize. [More]
Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations - detected after initial treatment with chemotherapy - are associated with an increased risk of relapse and poor survival. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery. [More]
Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer. [More]
Study sheds light on fertility concerns of young breast cancer patients

Study sheds light on fertility concerns of young breast cancer patients

Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back. [More]
FSU investigator solves cell division mystery

FSU investigator solves cell division mystery

In the second part of his lab's recent one-two punch, Florida State University researcher Daniel Kaplan said he has solved a cell division mystery in a way that will intrigue the makers of cancer-fighting drugs. [More]
Beta-blockers improve overall survival among epithelial ovarian cancer patients

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. [More]
UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas. [More]
Women diagnosed with ductal carcinoma in situ more likely to die from breast cancer

Women diagnosed with ductal carcinoma in situ more likely to die from breast cancer

Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general U.S. population, according to a new study led by Dr. Steven Narod. [More]
UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

UT Southwestern Medical Center researchers, in conjunction with NASA, will take four volunteer cancer patients on a zero-gravity ride into the upper atmosphere to study why zero-gravity conditions on the International Space Station sometimes affect the vision of astronauts staying there for extended periods. [More]
Advertisement
Advertisement